IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (NCT06112314)

🧪 Interventions in This Study

• Brenetafusp (DRUG)
• Nivolumab (DRUG)
• Nivolumab + Relatlimab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (211 Sites)

Showing the first 25 of 211 sites.

• University of Arizona — Tucson, Arizona
• University of California - San Diego — La Jolla, California
• The Angeles Clinic and Research Institute- West Los Angeles — Los Angeles, California
• ESC Norris Comprehensive Cancer Center — Los Angeles, California
• UCLA Hematology/Oncology — Los Angeles, California
• Stanford Cancer Institute - Stanford Cancer Center Palo Alto — Palo Alto, California
• Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
• University of Colorado, Anschutz Medical Campus — Aurora, Colorado
• The Melanoma & Skin Cancer Institute — Denver, Colorado
• UConn Health-Farmington (University of Connecticut Health Center (UCHC)) — Farmington, Connecticut
• Georgetown University — Washington D.C., District of Columbia
• Mayo Clinic Florida — Jacksonville, Florida
• University of Miami Health System-Sylvester Comprehensive Cancer Center-Miami — Miami, Florida
• Northwestern University - Robert H. Lurie Comprehensive Cancer Center - NMDTI — Chicago, Illinois
• The University of Kansas Cancer Center (KUCC) - Westwood — Westwood, Kansas
• St. Elizabeth Healthcare - Edgewood — Edgewood, Kentucky
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Cancer Center - Michigan — Detroit, Michigan
• Allina Health Cancer Institute - Minneapolis — Minneapolis, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
• Northwell Health Cancer Institute — Lake Success, New York
• Columbia University Medical Center — New York, New York
• The Ohio State University — Columbus, Ohio

📞 Contact the Study Coordinator

Phone: (844) 466-8661

Email: medical.information@immunocore.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Melanoma

• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Fairhope, Alabama
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Scottsdale, Arizona
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri

Explore by condition: All Advanced Melanoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.